Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival

  • Kim H.S.; 
  • Cho J.E.; 
  • Hwang K.C.; 
  • Shim Y.H.; 
  • Lee J.H.; 
  • 외 1명
Citations

SCOPUS

46

초록

Diabetes mellitus has been known to mitigate ischemic or pharmacologic preconditioning in ischemia-reperfusion injuries. Remifentanil is a widely used opioid in cardiac anesthesia that possesses a cardioprotective effect against ischemia-reperfusion. We evaluated whether diabetes affected remifentanil preconditioning induced cardioprotection in ischemia-reperfusion rat hearts in view of anti-apoptotic pathways of survival and Ca2+ homeostasis. Streptozotocin-induced, diabetic rats and age-matched wild-type Sprague-Dawley rats were subjected to a left anterior descending coronary artery occlusion for 30 min followed by 1 h of reperfusion. Each diabetic and wild-type rat was randomly assigned to the sham, ischemia-reperfusion only, or remifentanil preconditioning group. Myocardial infarct size, activities of ERK1/2, Bcl2, Bax and cytochrome c, and gene expression influencing Ca2+ homeostasis were assessed. Remifentanil preconditioning significantly reduced myocardial infarct size compared to ischemia-reperfusion only in wild-type rats but not in diabetic rats. Remifentanil preconditioning increased expression of ERK1/2 and anti-apoptotic protein Bcl-2 and decreased expression of pro-apoptotic proteins, Bax and cytochrome c, compared to ischemia-reperfusion only in wild-type rats. In diabetic rat hearts, however, remifentanil preconditioning failed to recover the phosphorylation state of ERK1/2 and to repress apoptotic signaling. In addition, diabetes minimized remifentanil induced modulation of abnormal changes in sarcoplasmic reticulum genes and proteins in ischemia-reperfusion rat hearts. In conclusion, diabetes mitigated remifentanil induced cardioprotection against ischemia-reperfusion, which might be associated with reduced recovery of the activities of proteins involved in anti-apoptotic pathways including ERK1/2 and the abnormal expression of sarcoplasmic reticulum genes as a result of ischemia-reperfusion in rat hearts. © 2009 Elsevier B.V. All rights reserved.

키워드

Diabetes mellitus; Ischemia-reperfusion; Remifentanil; calcium ion; cytochrome c; mitogen activated protein kinase 1; mitogen activated protein kinase 3; protein Bax; protein bcl 2; remifentanil; streptozocin; animal experiment; animal model; animal tissue; apoptosis; article; calcium homeostasis; controlled study; diabetes mellitus; enzyme activity; enzyme phosphorylation; gene expression; heart infarction; heart infarction prevention; heart infarction size; heart muscle reperfusion; heart protection; male; nonhuman; priority journal; protein expression; rat; signal transduction; streptozocin diabetes; wild type; Animals; Apoptosis; Cardiotonic Agents; Cell Survival; Diabetes Mellitus; Gene Expression Regulation; Heart; Hemodynamics; Ischemic Preconditioning, Myocardial; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardial Infarction; Myocardium; Phosphorylation; Piperidines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sarcoplasmic Reticulum
제목
Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival
저자
Kim H.S.; Cho J.E.; Hwang K.C.; Shim Y.H.; Lee J.H.; Kwak Y.L.
DOI
10.1016/j.ejphar.2009.11.032
발행일
2010
유형
Article
저널명
European Journal of Pharmacology
권
628
호
1-3
페이지
132 ~ 139